LEE011: Clinical Trials

40 trials of LEE011, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 13 terminated, 5 active not recruiting, 1 recruiting. 40 Phase 1, 11 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 140Completed 19, Terminated 13, Active not recruiting 5, Recruiting 1, Unknown 1, Withdrawn 1
Phase 211Terminated 4, Active not recruiting 3, Completed 3, Recruiting 1

Follow LEE011: new trials by email Literature Review of LEE011 trials Research Report on LEE011

Trials (filtered) newest first · largest first

All 40 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Topotecan, Temozolomide, Ribociclib - Neuroblastoma
Phase 1TerminatedNovartis Pharmaceuticals122022-12-272025-10-10
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
JDQ443, trametinib, Ribociclib - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals742022-10-242026-10-21
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Carboplatin, Docetaxel, Fulvestrant - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Phase 1 / Phase 2Active not recruitingJonsson Comprehensive Cancer Center182022-04-072026-05-11
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
Abemaciclib, Palbociclib, Quality-of-Life Assessment - Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma
Phase 1WithdrawnEmory University2020-06-122021-10-18
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
TNO155, Spartalizumab, Ribociclib - Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma
Phase 1TerminatedNovartis Pharmaceuticals1222019-07-302025-09-30
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
Ribociclib, Dexamethasone, Everolimus - Acute Lymphoblastic Leukemia ALL
Phase 1Active not recruitingDana-Farber Cancer Institute452019-01-302026-08-21
Ribociclib and Bicalutamide in AR+ TNBC
ribociclib, Bicalutamide - Triple Negative Breast Cancer
Phase 1 / Phase 2Active not recruitingKari Wisinski372018-05-072026-01-02
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma
Phase 1CompletedSt. Jude Children's Research Hospital682018-03-052024-05-31
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma
Phase 1CompletedPediatric Brain Tumor Consortium222018-01-132021-08-27
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Phase 1CompletedMayo Clinic432018-01-042023-01-05
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Ribociclib, PDR001, Fulvestrant - Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer
Phase 1TerminatedDana-Farber Cancer Institute332017-11-082025-05-31
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
LEE011, Everolimus - Metastatic Pancreatic Adenocarcinoma
Phase 1 / Phase 2CompletedGeorgetown University122017-05-042026-04-07
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma
Phase 1CompletedOHSU Knight Cancer Institute162017-03-102023-08-16
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Ribociclib, Topotecan, Temozolomide - Pediatric Cancer
Phase 1 / Phase 2RecruitingGustave Roussy, Cancer Campus, Grand Paris4722016-08-032026-07-10
Next Generation Personalized Neuroblastoma Therapy
Biopsy, Next Generation Sequencing, Tumor Scans - Neuroblastoma, Cancer
Phase 1TerminatedYael P Mosse662016-07-012026-03-10
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
ribociclib, Trametinib - Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II
Phase 1TerminatedNovartis Pharmaceuticals952016-06-292020-12-21
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
LSZ102, LEE011, BYL719 - Advanced or Metastatic ER+ Breast Cancer
Phase 1TerminatedNovartis Pharmaceuticals1992016-06-142022-08-01
A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
Ribociclib - High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Phase 1 / Phase 2TerminatedChildren's Hospital Medical Center, Cincinnati112016-04-012020-11-05
Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma
Ribociclib - Glioblastoma, Glioma
Phase 1UnknownUniversity of Virginia32016-03-012018-06-07
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
Tamoxifen, Ribociclib, Goserelin - Breast Cancer, Breast Cancer - Female
Phase 1CompletedH. Lee Moffitt Cancer Center and Research Institute72016-02-232022-01-21

Showing 20 of 40. Sign in to see all of them.

Conditions studied

Breast Neoplasms (8)  ·  Glioma (5)  ·  Neoplasms (5)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Colorectal Neoplasms (3)  ·  Medulloblastoma (3)  ·  Neoplasm Metastasis (3)  ·  Neuroblastoma (3)  ·  Recurrence (3)  ·  Brain Neoplasms (2)  ·  Diffuse Intrinsic Pontine Glioma (2)  ·  Glioblastoma (2)  ·  Liposarcoma (2)  ·  Lymphoma (2)  ·  Rhabdoid Tumor (2)

Sponsors

Novartis Pharmaceuticals (18)  ·  Dana-Farber Cancer Institute (2)  ·  Pfizer (2)  ·  Array BioPharma (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1)  ·  Emory University (1)  ·  Georgetown University (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Kari Wisinski (1)  ·  Mayo Clinic (1)  ·  OHSU Knight Cancer Institute (1)  ·  Pediatric Brain Tumor Consortium (1)

Countries

United States (33)  ·  France (12)  ·  Spain (11)  ·  Germany (10)  ·  Italy (10)  ·  Australia (8)  ·  Singapore (8)  ·  Belgium (7)  ·  Netherlands (6)  ·  United Kingdom (6)  ·  Canada (5)  ·  Japan (4)  ·  South Korea (4)  ·  Hong Kong (3)  ·  Taiwan (3)

Top investigators

Alex Adjei (1)  ·  Andrew E Place, MD, PhD (1)  ·  Array BioPharma (1)  ·  Benjamin Weinberg, MD (1)  ·  Birgit Geoerger, MD (1)  ·  Camilo Fadul, MD (1)  ·  David Mankoff, MD, PhD (1)  ·  Giles W. Robinson, MD (1)  ·  Jim Zhong (1)  ·  John M Maris, MD (1)  ·  Kari Wisinski, MD (1)  ·  Lara E Davis (1)  ·  Mariko D. DeWire-Schottmiller, MD (1)

Results publications

PMID 36800111, PMID 42334791, PMID 29059492, PMID 30941307, PMID 31399936, PMID 31538815, PMID 32354716, PMID 32619077, PMID 32669376, PMID 32887722, PMID 33034839, PMID 33555033, PMID 33892407, PMID 34347542, PMID 34433648, PMID 34543871, PMID 35292802, PMID 35294522, PMID 36969745, PMID 37580773, PMID 38746220, PMID 39809926, PMID 41838385, PMID 42686334

NIH funding

2015 (2), 2023 (2), 2009 (1), 2014 (1), 2016 (1), P30CA138292 (1), UM1CA081457 (1)